Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)
NCT00051077 · National Institute of Allergy and Infectious Diseases (NIAID) · PHASE2 · withdrawn · last registry update 2021-11-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, National Institute of Allergy and Infectious Diseases (NIAID) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IFNAR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-10-14Results posted on the registry: Faron Pharmaceuticals Ltd, IFN beta-1a + Dexamethasone (NCT04860518)
- 2022-10-12Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Tenofovir + Peginterferon-alfa 2a and tenofovir (NCT01369212)
- 2022-08-01Phase 3 first posted: PharmaEssentia, P1101 (Ropeginterferon alfa-2b-njft) + Ropeginterferon alfa-2b-njft (P1101) (NCT05481151)
- 2022-05-26Also stopped (terminated): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Entecavir and peginterferon (NCT01369199)
- 2022-04-21Results posted on the registry: Teva Branded Pharmaceutical Products R&D, Inc., Laquinimod + Placebo (NCT00605215)
- 2022-04-06Also stopped (withdrawn): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), hepatitis B immune globulin (HBIg) + Pegylated interferon alfa (pegIFN) (NCT03575208)
- 2022-02-16Phase 3 first posted: Cinnagen, Pegylated interferon beta-1a + Interferon Beta-1A Prefilled Syringe (NCT05242133)
- 2021-11-30Phase 3 first posted: AstraZeneca, Anifrolumab + Placebo (NCT05138133)
- 2021-11-24Results posted on the registry: AstraZeneca, Anifrolumab + Placebo (NCT02547922)
- 2021-11-22Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Interferon beta-1a + Remdesivir (NCT04492475)
- 2021-11-09Also stopped (withdrawn): Teva Branded Pharmaceutical Products R&D, Inc., Laquinimod + Avonex® (NCT01975298)
- 2021-10-06Results posted on the registry: University of Michigan Rogel Cancer Center, peg-IFN-α + Tacrolimus (NCT02328755)
- 2021-08-05Results posted on the registry: EMD Serono Research & Development Institute, Inc., Evobrutinib + Avonex® (NCT04032158)
- 2021-08-05Also stopped (terminated): EMD Serono Research & Development Institute, Inc., Evobrutinib + Avonex® (NCT04032158)
- 2021-08-05Results posted on the registry: EMD Serono Research & Development Institute, Inc., Evobrutinib + Avonex® (NCT04032171)
- 2021-08-05Also stopped (terminated): EMD Serono Research & Development Institute, Inc., Evobrutinib + Avonex® (NCT04032171)
- 2021-06-18Phase 3 first posted: AstraZeneca, Anifrolumab + placebo (NCT04931563)
- 2021-05-18Results posted on the registry: Johns Hopkins Bloomberg School of Public Health, Sofosbuvir + Daclatasvir (NCT03480932)
- 2021-05-07Phase 3 first posted: AstraZeneca, Medi-546 + Placebo (NCT04877691)
- 2021-04-15Results posted on the registry: Johns Hopkins Bloomberg School of Public Health, Sofosbuvir + Pegylated Interferon alfa-2a (NCT02541409)
- 2021-03-23Results posted on the registry: Ascletis Pharmaceuticals Co., Ltd., Danoprevir + Ritonavir (NCT03020082)
- 2021-03-09Phase 3 first posted: Novartis Pharmaceuticals, Ofatumumab + First line DMT (NCT04788615)
- 2021-02-25Results posted on the registry: Hepatera Ltd., Myrcludex B + PEG IFN alfa-2a (NCT02888106)
- 2021-02-11Results posted on the registry: Celgene, Ozanimod + Ozanimod placebo (NCT02047734)
- 2021-01-14Results posted on the registry: Faron Pharmaceuticals Ltd, Interferon Beta-1A + Placebo (NCT03119701)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision